What is the ticker symbol for Renalytix?

Renalytix trades under the ticker RNLX on NASDAQ.

What sector does Renalytix operate in?

Renalytix is classified in the Healthcare sector (Medical - Healthcare Information Services industry).

How can PortView help analyze RNLX in a portfolio?

PortView shows RNLX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Renalytix (RNLX) Stock Analysis

NASDAQHealthcareMedical - Healthcare Information Services

$0.21+5.66%

1-year price historyRange $0.15 – $1.47

52-week range$0.21

$0.18$2.40

What Renalytix does

Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.

Key metrics

Market cap

$22.55M

P/E (TTM)

-0.33

EPS (TTM)

$-0.62

Beta

2.10

Dividend yield

0.00%

Revenue / share

$0.04

50-day avg

$0.32

200-day avg

$0.52

52-week high

$2.40

52-week low

$0.18

CEO

James R. McCullough

ETFs linked to RNLX

Broad-market and Healthcare sector ETFs an investor holding Renalytix is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how RNLX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze RNLX in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Renalytix?: Renalytix trades under the ticker RNLX on NASDAQ.
Which exchange is RNLX listed on?: RNLX is listed on NASDAQ.
What sector does Renalytix operate in?: Renalytix is classified in the Healthcare sector (Medical - Healthcare Information Services industry).
How can PortView help analyze RNLX in a portfolio?: PortView shows RNLX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.